Floatz logo

Domvanalimab

Squamous Non Small Cell Lung Cancer

Arcus Biosciences, Inc.Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

54 Active assets in the Squamous Non Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Domvanalimab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
56 / 100
View asset →
hepatobiliary neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
peritoneal mesotheliomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →